Global Laparoscopic Power Morcellators Market is estimated to be valued at USD 137.4 Mn in 2024, and is expected to exhibit a CAGR of 7.3% over the forecast period (2024-2031).
Market Dynamics:
The increasing prevalence of gynecological conditions like uterine fibroids, endometriosis among women is expected to contribute to higher volumes of hysterectomy and myomectomy procedures. This, in turn, is anticipated to drive the demand for laparoscopic power morcellators as they are widely used for specimen extraction in such minimally invasive surgeries. Morcellation allows for the extraction of excised uterine tissue through smaller incisions compared to conventional abdominal hysterectomy. The associated benefits like lesser pain, scarring, and faster recovery times have led to a preference among surgeons and patients for laparoscopic techniques over open surgeries.
Growing Adoption of Minimally Invasive Surgeries are Driving Growth
The adoption of minimally invasive surgeries has increased significantly over the past decade. Minimally invasive surgeries offer several benefits over traditional open surgeries such as smaller incisions, less pain, reduced scarring, quicker recovery time and shorter hospital stays. Laparoscopic power morcellators are an essential equipment used in many minimally invasive surgeries such as hysterectomies and myomectomies to morcellate or cut tissues and organs into smaller pieces for easy removal through smaller incisions. The increasing acceptance of minimally invasive surgeries as the standard of care for various conditions is expected to drive higher demand for laparoscopic power morcellators during surgery.
Rise in Gynecological Conditions Propelling the Market Growth
Some of the most common medical conditions requiring surgical treatments are gynecological conditions such as uterine fibroids, endometriosis and abnormal uterine bleeding. It is estimated that over 200,000 hysterectomies are performed annually in the United States for the treatment of fibroids, uterine prolapse or other issues. Laparoscopic power morcellators enable effective and minimally invasive removal of the uterus or fibroid tissues during hysterectomy and myomectomy procedures. The rising incidence of gynaecological conditions globally is anticipated to boost the uptake of laparoscopic surgeries and subsequently drive the demand for power morcellators in the coming years.
Recalls Due to Safety Concerns Pose Challenge
The U.S. Food and Drug Administration (FDA) issued warnings about the use of laparoscopic power morcellators during uterine tissue removal procedures such as hysterectomy due to safety concerns. The FDA warned that morcellators may spread unsuspected cancerous tissues within the abdomen and pelvis, worsening the disease and reducing the chances of long-term survival. This led to several recalls of morcellator devices and seriously hampered market growth. The ongoing concerns regarding therisk of cancer spread with the use of power morcellators continue to discourage physicians and limit the adoption of these devices.
Reimbursement Uncertainties Hamper Market Penetration
The unregulated reimbursement scenario regarding minimally invasive gynecological procedures poses significant challenges to the market operators. There is no fixed reimbursement framework and coverage policies vary widely across public and private insurance plans. Physicians often face issues with coding, coverage and payment determinations. The financial risks and administrative difficulties involved in securing adequate reimbursement discourage healthcare facilities from investing in new surgical devices such as laparoscopic power morcellators. Unless reimbursement policies are streamlined and standardized, market expansion remains slow.
Development of Advanced Surgical Technologies are Opening Opportunities
Technological advancements are helping address some of the issues with earlier morcellator models. Newly developed tissue containment systems and morcellators with advanced blades aim to prevent cancerous tissue spread during morcellation. Single-use, cordless power morcellators suitable for office-based procedures are also gaining popularity. The ongoing improvements in morcellation device design focused on safety, usability and affordability could revive market confidence and support higher technological adoption. This presents significant opportunities for manufacturers.
Growing Demand for Minimally Invasive Gynecological Surgeries
The steady rise in gynecological surgical volumes worldwide is strongly favoring the adoption of minimally invasive procedures. Younger patients are increasingly opting for procedures that offer faster recovery times, smaller scars and less post-operative pain. This is spurring investments in minimally invasive surgical technologies across healthcare facilities. The widespread preference for Laparoscopic surgical techniques represents a major opportunity for manufacturers to promote the merits of advanced power morcellators and regain market share. With their ability to efficiently remove tissues, morcellators will continue gaining significance in performing MIS hysterectomy and myomectomy.
Link - https://www.coherentmarketinsights.com/market-insight/laparoscopic-power-morcellators-market-4905
Key Development
- In November 2022, Olympus Corporation, a medical device company, announced the launch of the more solution Power Morcellator, which is manufactured by TROKAMED GmbH and is available in the U.S. through a distribution agreement with Olympus America, Inc. The more solution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens.
- In February 2021, Olympus Corporation, a medical device company, indicated that it supported the U.S. Food and Drug Administration (FDA) published guidance recommendations suggesting that laparoscopic power morcellators in gynecological procedures must be performed using an approved containment device. Olympus Corporation is now the sole manufacturer having a 510(k)-cleared containment laparoscopic power morcellation device in the U.S.
Key Players: Medtronic, Karl Storz GmbH, Richard Wolf GmbH, LiNA Medical, Boston Scientific Corporation, Nouvag AG, Olympus Corporation, RUDOLF Medical GmbH, Blue endo, Hangzhou kangji medical instruments, and Advin Healthcare
